US vaccine companies have already been struggling, thanks to lessened demand since the peak of the pandemic. Over the past year, Pfizer stock has dipped 11%, and Moderna stock has plunged 46%.

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...